Work

Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC).

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.559

Authors: Rima Patel, Nadeem Bilani, Amy Tiersten, Joseph A. Sparano

Institutions: Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379284149

Cites:

Cited by: 2

Related to: 10